These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 8343610

  • 1. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B.
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [Abstract] [Full Text] [Related]

  • 2. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B.
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
    van Gerven JM, Lemkes HH, van Dijk JG.
    J Diabetes Complications; 1992; 6(1):45-8. PubMed ID: 1562758
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
    Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R.
    Ann Intern Med; 1993 Jan 01; 118(1):7-11. PubMed ID: 8416161
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA, Cameron NE, Hohman TC.
    J Peripher Nerv Syst; 1998 Jan 01; 3(3):217-23. PubMed ID: 10959252
    [Abstract] [Full Text] [Related]

  • 12. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].
    Daniele E, Coco MP.
    Clin Ter; 1995 Dec 01; 146(12):793-99. PubMed ID: 8681499
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.
    Macleod AF, Boulton AJ, Owens DR, Van Rooy P, Van Gerven JM, Macrury S, Scarpello JH, Segers O, Heller SR, Van Der Veen EA.
    Diabete Metab; 1992 Dec 01; 18(1):14-20. PubMed ID: 1563531
    [Abstract] [Full Text] [Related]

  • 15. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K.
    Diabetes Res Clin Pract; 1995 Feb 01; 27(2):107-17. PubMed ID: 7607048
    [Abstract] [Full Text] [Related]

  • 16. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
    Greene DA, Arezzo JC, Brown MB.
    Neurology; 1999 Aug 11; 53(3):580-91. PubMed ID: 10449124
    [Abstract] [Full Text] [Related]

  • 17. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.
    Diabetes Res Clin Pract; 2000 Oct 11; 50(2):77-85. PubMed ID: 10960717
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data.
    Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, Lachin JM.
    Diabetes Care; 1996 Oct 11; 19(10):1091-6. PubMed ID: 8886554
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.